Correspondence 0001178913-22-004452 from Artemis Therapeutics, Inc. (MNKA) (CIK 0001062128)
Artemis Therapeutics, Inc. (MNKA) (CIK 0001062128)
Date: Dec. 30, 2022 · CIK: 0001062128 · Accession: 0001178913-22-004452
AI Filing Summary & Sentiment
Reasoning
File numbers found in text: 333-267534
Letter
Artemis Therapeutics, Inc.
3 Eliezer Vardinon St.,
Petach Tikva, Israel 4959507
December 30, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Artemis Therapeutics, Inc. (CIK 0001062128)
Registration Statement No. 333-267534 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Artemis Therapeutics, Inc. (the “Registrant”) hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities Act”), so that it may become effective on January 4, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed offering of the securities specified in the Registration Statement.
Very truly yours,
ARTEMIS THERAPEUTICS, INC.
Show Raw Text
CORRESP
1
filename1.htm
Artemis Therapeutics, Inc.
3 Eliezer Vardinon St.,
Petach Tikva, Israel 4959507
December 30, 2022
VIA EDGAR
Securities and Exchange Commission
Division of Corporation Finance
100 F Street, N.E.
Washington, DC 20549
RE:
Artemis Therapeutics, Inc. (CIK 0001062128)
Registration Statement No. 333-267534 on Form S-1 (the “Registration Statement”)
Ladies and Gentlemen:
Artemis Therapeutics, Inc. (the “Registrant”)
hereby requests acceleration of the effectiveness of the above-referenced Registration Statement pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Securities
Act”), so that it may become effective on January 4, 2023, at 4:00 p.m., Eastern Time, or as soon thereafter as is practicable.
The Registrant understands that the Securities and Exchange Commission will consider this request for acceleration
of the effective date of the Registration Statement as a confirmation of the fact that the Registrant is aware of its responsibilities under the Securities Act and the Securities Exchange Act of 1934, as amended, as they relate to the proposed
offering of the securities specified in the Registration Statement.
Very truly yours,
ARTEMIS THERAPEUTICS, INC.
By:
/s/ Shimon Citron
Shimon Citron
Chief Executive Officer